




DISCLOSURES	
 Sage Products Speaker Bureau & Consultant Hill-Rom E.L. Lilly Merck 	

44,000 to 98,000 preventable death in hospitals related to medical errors annually (IOM report, 1999) 92,888 deaths directly attributable to safety indicators between 2005-2007 (HealthGrades 2009) Failure to rescue, pressure ulcers and post-op infections (VAP) Professional Nursing: Back to the Basics Quality organizations Safer HealthCare Now (SHN) & IHI Quebec Campaign: Together, lets improve healthcare safety Preventable injury is expensive











VENTILATOR ASSOCIATED PNEUMONIA

HOSPITAL ACQUIRED PNEUMONIA (HAP) AND VENTILATOR-ASSOCIATED PNEUMONIA(VAP)

- VAP crude mortality approximately 10-40%.
- HAP crude mortality 15-18%
- Pooled mean ranges 0.7 (Ped CVICU) to 7.4 (Burn ICU) per 1000 ventilator days
- HAP rates 5-15 per 1000 patient days
- Est cost \$30,000-\$40,000 per VAP
- Calculated loss for VAP against matched controls=\$12,780
- Increase LOS up to 4-14 days
- Annual cost \$2 billion dollars.

Edwards JR, et al. Am J of Infect Control, 2007;35:290-301 Kollef MH, et al. Chest, 2005:128:3854-3862 Colland HR. Ann Intern Med. 2003;138:494-501 Restrepo MJ, et al. Infect Control Hosp Epidemiol, 2010;31:509-515

Rello J. Chest. 2002;12:2115-2121 ATS Guidelines for HealthCare Acquired Pneumonia 2006 Coffin SE, et al. Infect Control & Hosp Epidemiol, 2008;29(1):S31-S40 Rosenthal VD, et al. Am J of Infect Control, 2008;36:6527-37


PAP IN CANADA Adult cases of VAP ~ 4000 per year 230 deaths 17,000 excess ICU days (2% of all ICU days in Canada) Costing 46 billion per year If 1 is prevented, cost savings of \$14,000.00 Controversy over the definition Safer Healthcare now supports reporting of VAP rates and compliance of bundle measures http://www.saferhealthcarenow.ca/EN/Interventions/VAP/Documents/VAP%20Getting%20Started%20Kit.pdf


VAP DIAGNOSIS Preventing VAP in Adult Patients Defining VAP in Adults Ventilator-associated pneumonia (VAP) is defined as a pneumonia occurring in patients requiring a device intermittently or continuously to assist respiration through a tracheostomy or endotrascheal tube. Further, the device must have been in place within the 48-hour period before onsere of infection and for at least consecutive days. Diagnostic criteria are as follows: a) Badographic abnormalities: New or progressive, and persistent chest radiographic opacity(ies) compatible with Pneumonia, e.g. infiltrate, consolidation or cavitation b) And at least 1 of the following: • WBC 2 12,000 or < 4,000 • Temperature > 286 c with no other cause c) And at least 2 of the following: • tracheal accretions: new onset of purulence, or change in character, or increase in volume • increase in suctioning requirements • inspiratory crackles (rales) or bronchial breath sounds on assicultation • Worsening gas exchange (e.g., O) desaturations; PaO₂/FIO₂c 240, an increase in oxygenation or ventilatory requirements.


Pneumonia Prevention – The Vent and Beyond Kathleen M. Vollman, Advanced Nursing

Teleclass broadcast sponsored by Sage Products (www.sageproducts.com)


DEFINITION IS CHANGING 1/2013: VENTILATOR ASSOCIATED EVENTS Foundation: Criteria: obiective. clinical data that are expected to be readily available across the spectrum of mechanically-ventilated patients, intensive care units and facilities New definition only for the following patients Patients ≥ 18 years of age; Patients who have been intubated and mechanically ventilated for at least 3 calendar days; and Patients in acute and long-term acute care hospitals and inpatient rehabilitation facilities. NOTE: Patients receiving rescue mechanical ventilation therapies (e.g., high-frequency ventilation, extracorporeal membrane oxygenation, or mechanical ventilation in the prone position) are excluded from surveillance using the new, proposed definition algorithm. Improving Surveillance for Ventilator-Associated Events in Adults Centers for Disease Control and tion www.APIC.org







No ventilator circuit change unless specifically indicated Alcohol based hand hygiene Appropriately educated and trained staff Incorporation of sedation and weaning protocols Oral care with CHG Relio J, et al. Intensive Care Medicine, 2010;36:773-780



HEALTHCARE ACOUIRED PNEUMONIA

- Risk Factor Categories
 - Factors that increase bacterial burden or colonization
 - Factors that increase risk of aspiration

MECHANICAL VENTILATION/ **INTUBATION**

- 6-21 times the risk for developing a pneumonia
- Removes normal filter mechanisms
- Facilitates entry of bacteria
- Decreases clearance of bacteria
- Colonization of the endotracheal tube
- Use of non-invasive positive pressure ventilation when indicated (COPD/CHF)
- Early (6-8 days) vs. late tracheotomy(13-15 days) did not reduce the risk of VAP or 28 day mortality in adults with

Tablan OC, et. al. CDC 1994 CDC. 2003 Guidelines for Prevention of Healthcare Associated Pneumonia; MMWR; 2004; S3(no RR-3) Xue Y, Joanna Briggs Institute, 2010. Terragni PP, et al. JAMA, 2010;303:1483-9

Mechanical Ventilation Wean Protocol **Bundle Element**

An automatic weaning protocol should be in place and mechanically ventilated patients should undergo assessment of readiness to wean & spontaneous breathing trial when they satisfy the 2- step process:

- Readiness to Wean: Arousable, Low ventilatory and end expiratory pressure requirements, No new potentially serious conditions, Hemodynamically stable without vasopressors, Requiring levels of FiO2 that could be delivered with a face mask or nasal cannula
- Perform a Spontaneous Breathing Trial: 30 to 120 minutes with assessment of vent pattern, gas exchange, hemodynamics. & comfort are 1999;159:512-18

Ely EW. N Engl J Med 1996;335:1864-69 Esteban A. Am J Respir Crit Care 1997;156:459465

APPROPRIATE SEDATION: IMPACTING VENTILATOR OUTCOMES

- Around the clock sedation administered via a protocol based on evaluation of sedative levels with a reliable and valid tool shorten time on vent, ICU & hospital length of stay, need for a trach*
- Daily interruption of sedative drug infusions decreases the duration of mechanical ventilation and LOS in the ICU In the group that had daily interruption, the duration of mechanical ventilation was reduced by 33% (2.4 days) and ICU LOS was reduced by 35% (3.5 days) and lower impact on PTSD.
- Wake up and breathe protocol resulted in Ψ time on ventilator, Ψ ICU & hospital stay and reduced 1 year mortality (NNT=7)
- When dexmedetomine was compared to midazolam in long term sedation, it showed Ψ time to extubation, Ψ ICU stay, Ψ delirium prevalence and ↑ delirium free days, problems with Bradycardia

Kress JP, et al. AM J Respir Crit Care Med, 2003;168:1457-1461 Brook AD, et al. Crit Care Med, 1999;27:2609-2615 Riker RR, et al. JAMA, 2009;301:489-499 Girard TD, et al. Lancet, 2008:371-126-134

Kress JP. et al. N Engl J Med. 2000;342:1471-1477

SNEAK PEEK AT NEW **GUIDELINES**

- PAD Guidelines Coming (Evidence Based)
 - Pain (Non-pharm & Pharmacological-Remifentanil or Fentanyl)
 - BPS (Behavioral Pain Scale)
 - CPOT (The Critical Care Pain Observation Tool)
 - Agitation (non-benzodiazepine, Dexmedetomidine or Propofol) light sedation & interruption
 - RASS
 - SAS
 - Delirium (use atypical antipsychotics-Olanzapine/Quetiapine
 - ICU-CAM
 - ICU Delirium Screening Checklist
- PAD Bundle

Presentedrate@GGM:201/20Eebruary

ENDOTRACHEAL / NASOGASTRIC TUBE/ SINUSITIS

- Carriage of oropharyngeal bacteria during intubation
- If cuff pressure < 20 cm 4x ↑ risk VAP
- Cuff pressure range btwn 25-40cm (JBI-Level A) with maintenance at 25cm-30cm of H2O pressure.
 - Continuous monitoring resulted in a lower portion of out of range cuff pressure (11% vs. 51.7% p< 0.001)
- NGT increases risk of sinusitis/gastric reflux & increases oropharyngeal colonization
- Use oral ET versus nasal (CDC-Cat IB)
- Sinusitis increases the risk of nosocomial pneumonia by 3

CDC. 2003 Guidelines for Prevention of Healthcare Associated Pneumonia MMWR; 2004:53(no RR-3)
Davis KA. J Intensive care Med, 2006;21(4):211-226
Muscedere J & Canadian Trails Group. J of Crit Care, 2008;23:126-137

Carstens J. Joanna Briggs Institute, 2010 Sole, ML, et al. AJCC, 2011;20:109-117

HEAD OF BED/ BUNDLE ELEMENT

BODY POSITION: SUPINE VERSUS SEMI-RECUMBENT (30-45 DEGREES)

Methodology

- 19 mechanically ventilated patients
- 2 period crossover trial
- Study supine and semirecumbent positions over 2 days
- Labeled gastric contents (Tc 99m sulphur colloid)
- Measured q 30 min content of gastric secretions in endobronchial tree in each position
- Sampled ET secretions, gastric juice & pharyngeal contents for bacteria

Torres A et. al Ann Intern Med 1992;116:540-543

BODY POSITION: SUPINE VERSUS SEMI-RECUMBENT (30-45 DEGREES)

Results

- Radioactive contents higher in endobronchial secretions in supine patients
- Time dependent:
 - Supine: 298cpm/30min vs. 2592cpm/ 300min
 - HOB: 103cpm/30min vs. 216cpm/300min
- Same microbes cultured in all 3 areas 32% with HOB vs. 68% supine.

Torres A et. al. Ann Intern Med 1992;116:540- 543

HOB RESEARCH

Methodology:

- 86 patients
- Randomly assigned to supine position or HOB 45 degrees (39 semi recumbent, 47 supine)
- Monitored clinical suspected & microbiologically confirmed nosocomial pneumonias

Results:

- Microbiologically confirmed nosocomial pneumonia lower in the semi recumbent group 2/39 (5%) vs. 11/47 (23%)
- Supine position & enteral nutrition were independent risk factors for VAP & had the greatest number of VAP's 14/28 (50%)

Drakulovic MB. et. al. Lancet. 1999;354:1851-1858

HOB RESEARCH

- Methodology
- Prospective multicenter trial randomly assigned to targeted 45° vs.10° HOB
- 112 to targeted 45° vs. 109 patients to 10°
- · Continuous measurement of backrest elevation first wk of MV
- Dx of VAP by bronchoscopic techniques
- Results
- Baseline characteristics similar
- Average elevations
- 10° group day 1 & 7: 9.8 & 16.1
- 45° group day 1 & 7: 28.1 & 22.6*
- Target 45° not achieved 85% of the time
 VAP: 10° = 6.5% vs. 45° = 10.7%

Van Nieuwenhoven CA, et al. Crit Care Med,


HOB ON VAP COMPARING 45° TO 25°

- Prospective randomized control trial comparing HOB elevation of 45 to 25 degrees on VAP rates
- There was no continual measurement of HOB or compliance with 45° was not measured
- Small sample size, 46% of randomized patients were withdrawn because of ventilation issues as well as discomfort.
- Results
 - VAP Rates: HOB 45 = 5/17


HOB 25 = 7/13


NursCrit Care 2007; 12: 287-94.


MAKING IT HAPPEN Entire team involvement Education on what 30 and 45 really look like Standing orders Contraindications (make it safe) www.saferhealthcar Visual strategies enow ca/EN/ Interventions/VAP/ Beds with angles built in Documents/VAP %20Getting · Tape on the wall %20Started Compliance measurements %20Kit.pdf



ORAL CAVITY & VAP • 89 critically ill patients • 49 elderly nursing home residents admitted to the hospital Examined microbial colonization of the oropharynx through out ICU stay • Examined baseline dental plaque scores & microorganism within dental plaque Used pulse field gel Used pulse field gel electrophoresis to compare electrophoresis to compare chromosomal DNA chromosomal DNA · Results: Results • Diagnosed 31 VAPs • 14/49 adults developed • 28 of 31 VAP's the causative pneumonia organism was identical via DNA analysis • 10 of 14 pneumonias, the causative organism was identical via DNA analysis Garrouste-Orgeas et. al. Am J Respir Crit Care Med. 1997;156:1647-1655 El-Solh AA. Chest. 2004:126:1575-1582







H₂ O₂, CETYLPYRIDIUM CHLORIDE (CPC) & BIOTENE

H_2O_2

- >3% may cause harm, <1% no benefit in plaque removal.
- Must be diluted properly, not with normal saline.
- 3x a day mouth rinse with 1.5% H₂ O₂ revealed no mucosal damage, improved plaque scores and overall gingival health.

CPC

- Cetylpyridium chloride had significant antigingivitis effects in several individual studies
- Used in some over the counter plaque reduction rinses (crest rinse)

Biotene

- Contains salivary enzymes
- . Moisturize. Some oral care kits

Gunsolley JC.J Am Dent Assoc 2006;137(12):1649-57 Gomes BC et.al. Clin Prev Dentistry. 1984; 6:21-25 Boyd RL. et. al. J Clin Periodentol.1989; 16:557-563

West TL et. al. Journal of Peridontol. 1983; 54(6):339
Tombes MA et. al. Nursing Research. 1993; 42(6):332-33

RECENT TRIALS REDUCTION IN VAP OR COLONIZATION WITH CHG OR POVIDONE-IODINE

- 2004: Grap (CHG via swab)
- 2005: Fourier (CHG) (negative trial)
- 2006: Koeman (CHG or CHG/colistin)
- 2006: Munro (CHG via swab & toothbrushing)
- 2006: Sequin (povidone-iodine)
- 2006: Mori (povidone-iodine)
- 2008: Tantipong (CHG)
- ◆ 2009, Sona (CHG)
- ◆ 2009, Panchabhai (CHG)—no decrease

PREVENTION OF VAP WITH ORAL ANTISEPSIS: A SYSTEMATIC REVIEW & META-ANALYSIS 14 studies evaluated from 1996 to 2011 2481 patients All randomize trials 9/14 blinded 12 trails assessed the effectiveness of CHG (2341 patients, 941 were CABG) 2 trials evaluated Povidone iodine (140pts) Variation of additional interventions; toothbrushing, oropharyngel aspiration mechanical cleaning of the mouth · Frequency of antiseptic P=0.004 Labaeu SO, et.al. Lancet. 2011;11:845-854

COMPREHENSIVE ORAL CARE PROGRAM/BUNDLE ELEMENT

- Soft suction tooth brush x2 daily
- · CHG rinse .12% 2x daily,
- Suction Oral Swab, use of a 1.5% H₂O₂ peroxide mouth rinse or CPC for in between cleaning
- Deep oral suctioning catheter used 4x daily
- Covered yankauer for non-traumatic oral suctioning
- Dedicated oral suction line for infection control and ease of use.



Schleder B. et al. J Advocate Health 2002;4(1):27-30 Murray TM et al. AACN Advanced Critical Care. 2007;18(2):190-199

COMPREHENSIVE ORAL CARE PROTOCOL: THE GOOD SHEPHERD STUDY

Methodology:

- Retrospective study 10 bed Med-Surg
- Protocol included: Covered Yankauer for non-traumatic oral suctioning, soft-suction toothbrush, Suction Oral Swab, use of a 1.5% H₂O₂ peroxide mouth rinse for cleansing, subglottic suction catheter used 4x daily, dedicated oral suction line for infection control and ease of use.
- Education provided and presence of clinical champion.

Schleder B. et al. J Advocate Health 2002;4(1):27-30


LITERATURE REVIEW: ORAL CARE IMPACT OF VAP


Comprehensive Oral Care:


- Reduction in VAP from 5.6 to 2.2 (Schleder B. et al. J Advocate Health 2002;4(1):27-30)
- Reduction in VAP from 4.10 (2005) to (2.15) in 2006 with addition of CPC & comprehensive oral care. Vent bundle & rotational therapy already being performed


Pneumonia Prevention – The Vent and Beyond Kathleen M. Vollman, Advanced Nursing


Teleclass broadcast sponsored by Sage Products (www.sageproducts.com)

















SSCM NUTRITIONAL GUIDELINES (2009)

- Targeted for ICU pts > 2 3 day LOS
- ARDS/Severe ALI=EN formula with anti-inflammatory lipid profile (Grade A)
- Nutritional therapy in form of EN should be initiated in patients unable to maintain voluntary intake (Grade C)
- EN preferred route (Grade B), EN start 24-48hrs (Grade C), advance towards goal over next 48-72hrs (Grade E)
- EN withheld until unstable patient fully resuscitated (Grade E)
- Neither presence or absence of bowel sounds, or passage of flatus or stool required before initiation (Grade B)
- Either gastric or small bowel feeding acceptable. If at high risk feed via small bowel (Grade C)
- Hold for gastric residuals > 500 ml in absence of other signs of intolerance (Grade B)


Martindale RG, et al. Crit Care Med, 2009;37:1757-1761







CLRT TO PREVENT VAP Methodology Prospective randomized controlled trial, 3 medical ICUs at a single center Eligible if ventilated < 48 hours & free from pneumonia, ALI or in ARDS 150 patients with 75 in each group 35 CLRT patients allocated to undergo percussion before suctioning Measures to prevent VAP were standardized for both groups including HOB Results: CLRT vs. Control VAP: 11% vs. 23% p = .048 Ventilation duration: 8 ± 5 days vs. 14 ± 23 days, p = .02 LOS: 25 ± 22 vs. 39 ± 45 days, p = .01 Mortality: no difference



OUTCOMES OF A PROGRESSIVE MOBILITY PROGRAM

- ψ time on the ventilator
- ↓ incidence of VAP
- 4 days of sedation
- ↓ delirium
- ↑ ambulatory distance
- Improved function


Staudinger t, et al. Crit Care Med, 2010;38. Abroung F, et al. Critical Care, 2011;15:R6 Morris PE, et al. Crit Care Med, 2008;36:2238-2243 Pohlman MC, et al. Crit Care Med, 2010;38:2089-2094 Schweickert WD, et al. Lancet, 373(9678);1874-82. Thomsen GE, et al. CCM 2008;36:1119-1124 Winkelman C et al, CCN2010;30:36-60


Intervention to Decrease VAP Statewide Collaborative-Keystone ICU

- 112 ICU's from 72 hospitals reported data
- Examine 550,800 ventilator days
- · Implementation of the CUSP/VAP Bundle/checklist
- - Median rate of VAP per 1000 vent days went 5.5 cases to 0 0 at 16-18 months (p<0.001) & 0 at 28-30 months (p<.001)
 - Mean rate of VAP per 1000 vent days went 6.9 to 3.4 at 16-18 month follow up (p<0.001) & 2.4 at 28 to 30 months (p<.001)
 - Composite compliance measured ↑ from 32% at baseline, 75% at 18 months & 84% at 28 months
 - · Inclusion of oral care was not measured

Berenholtz SM, et al. Infect Control Hosp Epidemiol, 2011;32:305-314







Evaluate: project leader monitors that teens are using standardized definitions, report their data and make it transparent at the unit level

Goeschel CA, et al. Nursing in Critical Care, 2011;16:35-42





FOUR E'S - Engage: help staff understand the preventable harm - Share stories about patients affected - Estimate number of patients harmed - Develop a business case - Educate: ensure staff and senior leaders understand what they need to do to prevent injury and improve teamwork and communication - Conference calls, webcasts, meetings - Execute: how given the resources and culture they would ensure that all patients received the evidence - Share with working, what's not - Coaching calls - Evaluate: project leader monitors that teens are using standardized definitions, report their data and make it transparent at the unit level


EXECUTE								
"Ventilator-Associated preummonia" When the control of the contro	**Product Antonioses** The control of the control							
Ballyan 1997-In-July								
	1 std							


EXECUTE											
Board Checklist			Executive/Senior Leader Checklist								
Prevent Ventilator Associated Pneumonia "VAP"	Le oder Responsible	Date Initiated	Prevention of Ventilator Associated Pneumonia "VAP"	Leader Responsible	Date Initiated						
 Set organization airs to assess annually safety and teamwork climate annually and improve it using valid measures. 			Ensure science of safety training for all current and new employees (www.safercare.net).								
 Hold Executive team accountable for explicit action plan to improve safety and teamwork climate. Review progress recrifity. 			Assign leader (CEO or another leader) as an active member of the VAP to any, meet with the team on the unit a least monthly, leat the staff home senior leaders are invested and will work as hard as they do to make it a success.								
 Establish policy that requires science of safety training for all current and new employees and board numbers (<u>www.safercare.net</u>). 											
 Set expectation that a senior leader is an active member of the VAP team and meets with the team on the unit at least monthly. 					-						
Hear at least one patient-level Story of Harm from infection at each board meeting.			leaders and staff in critical care units. Provide opportunities for project teams to meet with senior leaders and the board to discuss the project.								
 Work with CEO and CMO to establish interdisciplinary patient rounds as an organization standard of practice. 			Create a policy for unit level accountability:								
 Define organization goal of WAP reduction over 3-5 years. Target is a mean WAP rate of < 1 infection per 1000 ventilator days and a median of 2 year. 			document learning from at least one defect per month.								
Review unit level WAP rates at least quarterly at full Board receting.			 Foster organizational learning disseminate learning from defect lessons with expectations for local adaptation. 								
 Establish account ability process to investigate each infection, dose the loop, and report back to the board. 			Require use of a patient specific daily goals checklist.								
 Require OFO to provide quarterly review of VAP cases subject to CMS pay for performance and the financial impact per case. 			 Codify interdisciplinary rounds as an organization- level standard of practice; support local 								
 Establish audit reschanism to sessere adversince with rigorous data quality standards. Review audit reports quarterly. 			interpretation based on unit characteristics. 8. Acknowledge work of teams: celebrate success								
 Hold CEO and Executive team accountable for VAP reduction through performance-based compensation 			through stories in hospital newsletter, apportunities for teams to share with management and other teams								
 Require amonthly report of horn that includes the number of people infected such month, compliance rate for following the evidence based guidelines to prevent WAP, and hand hydren compliance 			Make elimination of VAP an organization-wide goal; include in strategic plan.								
 Assure that the board reviews all infection-related sentinel events, liability dains, medical staff disciplinary actions, and patient complaints. 			 Develop a coordinated plan for VAP reduction throughout the organization. 								
			Provide protected time for VAP reduction team leaders: doctor: nurse, data collector (approx. 10%)								

		ΧE	CUTE				
Infection Preventionist Ch	Infection Preventionist Checklist			Nurse Leader (Unit Director/Manager) Checklist			
Prevent Ventilator Associated Pneumonia "VAP"	Leader Responsible	Date Initiated	Prevention of Ventilator Associated Pneumonia "VAP"	Leader Responsible	Date Initiated		
Meet with CEO and hospital project leader to understand the initiative and the Infection Prevention roles. (Units must own and lead the project, but infection preventionists (IP) have a critical "expert" role.) Infroduce the project to all IP staff and explain their			 Meet with GEO and hospital project leader to understand the initiative and the infection Prevention roles. (Units must own and lead the project, but infection control practitioner (ICP) have a critical "expert" role) 				
role 3. Require science of safety training for all current and new IP staff (www.safercare.net)			Introduce the project to all unit staff and explain their role				
Assign on IP to VAP team; expect them to contribute actively to monthly team meetings. Participate in project meetings.			Require science of safety training for all current and new staff (www.safercare.net)				
Learn from Defects: work with unit teams to investigate each VAP and report findings across institution			 Assign a team leader or unit charaptor; expect them to contribute actively to monthly team meetings. 				
Shadownurses; arrange for nurses to shadow IP's Identify and mitigate barriers to prevent VAP. Observe Ventilator Management Core. Ask clinicians what is difficult. Collaborate to premove horizon.			 Learn from Defects: work with the unit team leader to investigate each VAP and report findings across institution 				
Collaborate with Clinical and Administrative leaders to develop a coordinated plan for VAP reduction throughout the organization			Train the Unit Leader to Shadow nurses; arrange for nurses to shadow IOF's				
Assure that all IP staff are skilled in use of CD C VAP definitions and surveillance methods Maintain active infection surveillance program using			Identify and mitigate barriers to prevent VAP. Audit compliance to evidence based VAP prevention bundle. Validate by observing ventilator				
CDC criteria 12. Monitor hand hygiene no less than quarterly and report performance to all employees and the Board			management care on the bedside. Ask clinicians what is difficult. Collaborate to remove barriers.				
Ensure accuracy and efficacy of staff education on strategies to prevent VAP 14. Provide monthly unit level VAP data to project leads			Collaborate with Clinical and Administrative leaders to develop a coordinate diplan for VAP reduction throughout the organization				
for POSTING and transparent tracking. 15. Send senior hospital leaders unit specific, weekly reports of the number of people infected with VAP, the weeks without VAP, and ounterfer VAP rates.			Collaborate with the IOP staff on surveillance methods				
 Lead efforts to assess utility and necessity of infection related technologies: special OETTs with continuous subglottic suctioning , HOB 			Maintain active infection surveillance program using CDC oriteria Collaborate with the ICP on Monitoring hand				
Alertfindinator, basinless bath care, Chlorhexidine oral care kits. 17. Enter VAP data into the NHSNYCDC website to ensure accuracy and focused analysis, data integrity.			 Collaborate with the ICP on Monitoring hand hygiene. Report performance to all employees and senior leaders. 				










POTENTIAL BARRIERS

- Perception of lack of time or the importance
- Lack of evidence based education...just do it!!!!
- Absence of a define protocol/procedure
- Staff turnover/Replacement staff
- Inaccessibility of needed supplies
- No real clinical lead on the unit
- Lack of feedback on progress
- Lack of accountability/responsibility

O'keefe-McCarthy S, et al. Worldviews on Evidence Based Nursing, 2008:193-204 Abott CA, et al. Worldviews on Evidence Based Nursing:2008:193-204



- Evidence based education
- Recognition of value and reinforcement
- Products/Processes that make it easy for the frontline caregiver to provide the care (make it part of the bundle)
 - Bathing kits
 - · Placement on the med record
 - Automated charting with flag reminders
- Frequent rounding/reinforcement of standard
- Multidisciplinary rounds/Checklists



BE COURAGEOUS

We all are responsible for the safety of our patients.....Own the Issues

- "If not this, then what??"
- "If not now, then when?"
- "If not me, then who??"

